Wanbury Ltd says operations and FY27 guidance remain unaffected, with Tanuku’s US-market exposure at ~6% of consolidated YTD revenue
- Tanuku facility’s US-market exposure remains unaffected.
- New ANDAs and filings will be handled by the US FDA-approved Patalganga facility.
- The company said its assessment of operations and FY27 guidance is unchanged.
